SecBot SecBot
S-4/A ·Filed Nov 10, 2026

HOWL

Werewolf Therapeutics, Inc.
NEUTRAL
Impact 5/10
Horizonweeks Processed6d 8h ago SEC0001140361-26-043046
Notable filing: S-4/A
Actionable Insight • Neutral

The merger is a transformative reverse acquisition that will give Ambros a public listing and capital via the PIPE. Werewolf holders face massive dilution (to ~6.4% of the combined entity) but receive CVRs tied to legacy asset sales. The key binary event is the December 17 stockholder vote; failure to approve the required proposals would terminate the deal and likely force Werewolf into dissolution or another strategic transaction.

DirectionNeutral
Confidencehigh
Horizonweeks

neridronate

● Neutral Named in this S-4/A
Impact
Phase
Phase 3
Time to market
Topline Phase 3 results expected in 2028, NDA submission thereafter, potential FDA approval likely no earlier than 2029 if the trial succeeds.
Next catalyst
None dated

What to watchWatch for the timing and outcome of the CRPS-RISE interim analysis, which could allow the trial to stop early for efficacy or futility. The merger with Ambros is still being finalized (S-4/A filed November 10, 2026), and current HOWL shareholders face massive dilution, owning roughly 7% of the combined entity. The $150 million PIPE is expected to fund the company through topline results in 2028 and into 2029, reducing near-term financing risk.

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1
Entry
$0.9889
T+0 close · Nov 10, 2026 · via day close
Latest settled
−0.90%
T+1 · $0.9800
Vs SPY
−0.55%
α at T+1
Next horizon
T+5
tomorrow
  1. T+0 · Nov 11 $0.9889entry
  2. T+1 · 5d ago −0.90%α −0.55% · $0.9800
  3. T+3 · todayOpen
  4. T+5 · tomorrow Pending
  5. T+20 · in 23d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Werewolf Therapeutics filed Amendment No. 2 to its S-4 registration statement for the proposed reverse merger with Ambros Therapeutics. Under the merger agreement, Ambros (valued at $500M) will become a wholly owned subsidiary of Werewolf, which will rename to Ambros Therapeutics. A concurrent $150M PIPE financing will close alongside the merger. Pre-merger Werewolf holders will own approximately 6.4% of the combined company, Ambros holders approximately 72.0%, and PIPE investors approximately 21.6%. The combined company will focus on Ambros' lead candidate neridronate for CRPS-1. Werewolf stockholders must approve several proposals at a December 17, 2026 special meeting for the merger to close, expected by Q1 2027.

Key Facts

  • Ambros equity value set at $500.0 million, Werewolf at $47.5 million
  • Concurrent PIPE financing of $150.0 million with minimum $100.0 million condition
  • Estimated exchange ratio: 10.7623 Werewolf shares per Ambros share
  • Post-merger ownership: Werewolf holders 6.4%, Ambros holders 72.0%, PIPE investors 21.6%
  • Combined company to trade on Nasdaq under symbol AMBX
  • Werewolf stockholders to receive CVRs for legacy WTX-124 and WTX-330 programs
  • Special meeting scheduled for December 17, 2026; closing expected Q1 2027
  • Werewolf had $22.0M cash as of June 30, 2026 and accumulated deficit of $485.3M
  • Ambros had $103.2M cash as of June 30, 2026 and accumulated deficit of $60.8M
  • Werewolf received Nasdaq deficiency notice for minimum bid price non-compliance

Financial Impact

Ambros valued at $500M equity; $150M PIPE; combined company cash runway into first half of 2029

dilutioncash positionownership structure

Risk Factors

  • Stockholder approval of required proposals is not guaranteed; failure would terminate the merger
  • Nasdaq listing condition for combined company shares may not be satisfied
  • Werewolf faces going concern risk if merger fails; would need additional funding or dissolution
  • Ambros' lead candidate neridronate has prior Phase 3 failures by Grnenthal; CRPS-RISE trial may not succeed
  • Massive dilution for existing Werewolf holders (to 6.4% of combined company)

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
0% bullish (6 analysts)

Investment Themes

Documents Analyzed

This report is based on 9 SEC documents filed with EDGAR.

DocumentAccession Number
S-4/A Filing (Primary)0001140361-26-043046
Document: ny20081588x4_ex107.htm0001140361-26-043046
Document: ny20081588x4_ex5-1.htm0001140361-26-043046
Document: ny20081588x4_ex99-1.htm0001140361-26-043046
Document: ny20081588x4_ex23-2.htm0001140361-26-043046
Document: ny20081588x4_ex23-1.htm0001140361-26-043046
Document: 0001140361-26-043046-index-headers.html0001140361-26-043046
Document: 0001140361-26-043046-index.html0001140361-26-043046
Document: 0001140361-26-043046.txt0001140361-26-043046

Track record

31 reports on HOWL

Performance horizon

12 of 16 bullish or bearish reports moved the stock their way by T+5. Best: +51.32% at T+60 after the Apr 27, 2026 report. 13 of 16 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G Neutral 4/10 Entry $0.9500 Now $0.9910 +4.32% settles Nov 23
  2. Nov 13, 20264d ago EFFECT Neutral 4/10 Entry $0.9803 Now $0.9910 +1.09% settles Nov 20
  3. Nov 10, 20266d ago S-4/A Neutral 5/10 Viewing Entry $0.9889 Now $0.9910 +0.21% settles Nov 18
  4. Nov 9, 20267d ago 425 Neutral 5/10 Entry $0.9700 Now $0.9910 +2.16% settles Nov 17
  5. Nov 9, 20267d ago 8-K Neutral 5/10 Entry $1.01 to $0.9908 Now $0.9910 −1.88% ▼ −1.90% −0.21% vs SPY
  6. Nov 9, 20267d ago Press Release Neutral 5/10 Entry $1.01 to $0.9908 Now $0.9910 −1.88% ▼ −1.90% −0.21% vs SPY
  7. Oct 26, 202621d ago S-4/A Bearish 5/10 Entry $1.04 to $1.07 Now $0.9910 +4.71% ▼ −2.88% −4.87% vs SPY
  8. Sep 22, 20267w ago S-4 Bearish 7/10 Entry $0.9894 to $0.9223 Now $0.9910 −0.16% ▲ +6.78% +6.11% vs SPY
  9. Sep 21, 20268w ago SC 13G Neutral 3/10 Entry $0.9800 to $0.9300 Now $0.9910 +1.12% ▼ −5.10% −4.08% vs SPY
  10. Aug 21, 202612w ago 425 Bullish 7/10 Entry $0.8740 to $0.9433 Now $0.9910 +13.39% ▲ +7.93% +7.46% vs SPY
Showing 10 of 31

US Market Status

Market Closed · Opens in 8h 20m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 10, 2026